No annual revenue total was found in BRAINSTORM CELL THERAPEUTICS INC.'s SEC filings.
Brainstorm Cell Therapeutics Inc. (BCLI) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $22,000 in cash and investments and $1.4 million in total debt.
Revenue
—
Net income (TTM)
$-10.52M
+8.1% vs year-ago TTM
Operating cash flow (TTM)
$-4.06M
+57.2% vs year-ago TTM
Free cash flow
$-20.48M
-5.8% vs prior year
EPS (TTM)
$-0.95
+45.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
11.03M
+69.2% vs prior year
Net cash
$-1.35M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCLI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1137883
- Former names
- BRAINSTORM CELL THERAPEUTICS INC (until Jul 23, 2012); GOLDEN HAND RESOURCES INC (until Nov 22, 2004); WIZBANG TECHNOLOGIES INC (until Aug 8, 2003)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$10.0M | -$11.7M | -$21.4M | -$24.8M | -$24.5M |
| Net income | -$10.3M | -$11.6M | -$17.2M | -$24.3M | -$24.5M |
| Diluted EPS | -$1.11 | -$2.31 | -$6.00 | -$0.66 | -$0.68 |
| Operating cash flow | -$7.0M | -$9.1M | -$20.5M | -$19.3M | -$26.3M |
| Free cash flow | — | — | -$20.5M | -$19.3M | -$26.6M |
| Total assets | $1.0M | $1.8M | $4.2M | $8.5M | $29.3M |
| Total liabilities | $11.0M | $9.6M | $9.1M | $11.5M | $9.9M |
| Stockholders' equity | -$10.0M | -$7.8M | -$4.9M | -$3.0M | $19.3M |
| Cash and investments | $29,000 | $187,000 | $1.3M | $3.0M | $22.1M |
| Total debt | $1.2M | $720,000 | $1.3M | $4.1M | $5.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 30, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 28, 2026 | May 25, 2026 |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
All 949 Brainstorm Cell Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.